{"id":6718,"date":"2011-03-03T10:32:55","date_gmt":"2011-03-03T15:32:55","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=6718"},"modified":"2011-07-19T17:44:31","modified_gmt":"2011-07-19T21:44:31","slug":"5-year-followup-of-accord-still-no-support-for-intensive-glucose-lowering","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/03\/03\/5-year-followup-of-accord-still-no-support-for-intensive-glucose-lowering\/","title":{"rendered":"5-Year Followup of ACCORD: Still No Support For Intensive Glucose Lowering"},"content":{"rendered":"<p>Long-term followup of the\u00a0Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial\u00a0has once again failed to support routine intensive glucose lowering in high-risk type 2 diabetics. In 2008, as\u00a0<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0802743\">reported in the <\/a><em><a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0802743\">New England Journal of Medicine<\/a><\/em>, the intensive glucose-lowering regimen (target glycated hemoglobin level of &lt;6%) was terminated early after an increase in mortality was observed in that group, and all patients received standard glucose-control therapy (target glycated hemogloblin level of 7.0% to 7.9%).<\/p>\n<p>Now, <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1006524\">a new paper in <em>NEJM<\/em><\/a> reports the 5-year results of the trial, after 3.7 years of intensive glucose-lowering treatment and up to 17 months of additional followup. Mortality at 5 years was 19% higher in the intensive-control group (7.6% in the intensive-therapy group versus 6.4% in the standard-therapy group). By contrast, the incidence of nonfatal myocardial infarction was lower in the intensive-therapy group, although cardiovascular deaths were higher in this group.<\/p>\n<p>In their conclusion, the ACCORD investigators write that the results &#8220;suggest a lower limit for glycemic targets, achieved with the use of multiple combinations of currently available approaches.&#8221;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Long-term followup of the\u00a0Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial\u00a0has once again failed to support routine intensive glucose lowering in high-risk type 2 diabetics. In 2008, as\u00a0reported in the New England Journal of Medicine, the intensive glucose-lowering regimen (target glycated hemoglobin level of &lt;6%) was terminated early after an increase in mortality was [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[723,468,469],"class_list":["post-6718","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-accord","tag-glucose-control","tag-type-2-diabetes"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=6718"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6718\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=6718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=6718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=6718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}